MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.96
-0.81
-1.70%
Pre Market: 48.20 +1.24 +2.64% 08:09 03/31 EDT
OPEN
48.00
PREV CLOSE
47.77
HIGH
48.45
LOW
45.08
VOLUME
829.87K
TURNOVER
--
52 WEEK HIGH
163.43
52 WEEK LOW
38.95
MARKET CAP
2.61B
P/E (TTM)
-3.2832
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLUE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLUE stock price target is 115.65 with a high estimate of 221.00 and a low estimate of 70.00.

EPS

BLUE News

More
  • What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One
  • Investor's Business Daily · 13h ago
  • Cell and gene therapy firm raises $170M investment
  • American City Business Journals · 19h ago
  • Stocks To Watch: Investors Stay The Distance
  • Seeking Alpha - Article · 2d ago
  • Stifel likes bluebird bio in premarket analyst action
  • Seeking Alpha - Article · 4d ago

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About BLUE

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.